All Stories

  1. Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients

    Article • Leukemia & Lymphoma, January 2019, Taylor & Francis

    Dimitrios Ziogas

  2. Prognostic factors for multiple myeloma in the era of novel therapies

    Article • Expert Review of Hematology, October 2018, Taylor & Francis

    Dimitrios Ziogas

  3. Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis

    Article • Amyloid, October 2018, Taylor & Francis

    Dimitrios Ziogas

  4. Treating ALK-positive non-small cell lung cancer

    Article • Annals of Translational Medicine, April 2018, AME Publishing Company

    Dimitrios Ziogas

  5. Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?

    Article • Annals of Translational Medicine, April 2018, AME Publishing Company

    Dimitrios Ziogas

  6. Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis

    Article • Blood, January 2018, American Society of Hematology

    Dimitrios Ziogas

  7. POEMS Syndrome

    Article • January 2018, Springer Science + Business Media

    Dimitrios Ziogas

  8. The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents

    Article • Blood, November 2017, American Society of Hematology

    Dimitrios Ziogas

  9. An overview of the role of carfilzomib in the treatment of multiple myeloma

    Article • Expert Opinion on Pharmacotherapy, November 2017, Taylor & Francis

    Dimitrios Ziogas

  10. Gefitinib: an “orphan” drug for non-small cell lung cancer

    Article • Expert Opinion on Orphan Drugs, October 2017, Taylor & Francis

    Dimitrios Ziogas

  11. Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases

    Article • Leukemia & Lymphoma, August 2017, Taylor & Francis

    Dimitrios Ziogas

  12. Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit

    Article • Blood Cancer Journal, June 2017, Nature

    Dimitrios Ziogas

  13. Circulating autoantibodies to endogenous erythropoietin are associated with chronic hepatitis C virus infection-related anemia

    Article • Hepatobiliary & Pancreatic Diseases International, June 2017, Elsevier

    Dimitrios Ziogas

  14. Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy

    Article • American Journal of Hematology, May 2017, Wiley

    Dimitrios Ziogas, Ioannis Papassotiriou

  15. Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT without Dexamethasone and Bisphosphonates: Final Analysis of a Prospective Study

    Article • Clinical Lymphoma Myeloma & Leukemia, February 2017, Elsevier

    Dimitrios Ziogas

  16. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma

    Article • European Journal of Gastroenterology & Hepatology, January 2017, Wolters Kluwer Health

    Dimitrios Ziogas

  17. Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens

    Article • Leukemia & Lymphoma, December 2016, Taylor & Francis

    Dimitrios Ziogas

  18. When to recommend a second autograft in patients with relapsed myeloma?

    Article • Leukemia & Lymphoma, November 2016, Taylor & Francis

    Dimitrios Ziogas

  19. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma

    Article • Haematologica, October 2016, Ferrata Storti Foundation (Haematologica)

    Dimitrios Ziogas

  20. Evaluation of the Revised International Staging System (R-ISS) in an Independent Cohort of Unselected Patients with Multiple Myeloma

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2016, Elsevier

    Dimitrios Ziogas

  21. Carfilzomib for treating myeloma

    Article • Expert Opinion on Orphan Drugs, August 2016, Taylor & Francis

    Dimitrios Ziogas

  22. Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment

    Article • Blood Cancer Journal, May 2016, Nature

    Dimitrios Ziogas

  23. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis

    Article • American Journal of Hematology, April 2016, Wiley

    Dimitrios Ziogas

  24. Predicting the Outcome of Sjogren’s Syndrome-Associated Non-Hodgkin’s Lymphoma Patients

    Article • PLoS ONE, February 2015, PLOS

    Dr Clio P Mavragani, Dimitrios Ziogas

  25. Asymptomatic Bacteriuria in Women With Autoimmune Rheumatic Disease: Prevalence, Risk Factors, and Clinical Significance

    Article • Clinical Infectious Diseases, November 2014, Oxford University Press (OUP)

    Dimitrios Ziogas

  26. Inflammation-induced functional connectivity of melanin-concentrating hormone and IL-10

    Article • Peptides, May 2014, Elsevier

    Dr Beatriz Gras-Miralles, Dimitrios Ziogas

  27. Intestinal Upregulation of Melanin-Concentrating Hormone in TNBS-Induced Enterocolitis in Adult Zebrafish

    Article • PLoS ONE, December 2013, PLOS

    Dr Beatriz Gras-Miralles, Dimitrios Ziogas

  28. Anti-melanin-concentrating hormone treatment attenuates chronic experimental colitis and fibrosis

    Article • AJP Gastrointestinal and Liver Physiology, May 2013, American Physiological Society

    Dimitrios Ziogas

  29. Increased Susceptibility of Melanin-Concentrating Hormone-Deficient Mice to Infection with Salmonella enterica Serovar Typhimurium

    Article • Infection and Immunity, October 2012, ASM Journals

    Dimitrios Ziogas

  30. Catechol-O-Methyltransferase val158met Polymorphism Predicts Placebo Effect in Irritable Bowel Syndrome

    Article • PLoS ONE, October 2012, PLOS

    Kathryn T Hall, Dimitrios Ziogas

  31. Reduced Intestinal Tumorigenesis in APCmin Mice Lacking Melanin-Concentrating Hormone

    Article • PLoS ONE, July 2012, PLOS

    Dr Beatriz Gras-Miralles, Dimitrios Ziogas

  32. The reporting quality of studies investigating the diagnostic accuracy of anti-CCP antibody in rheumatoid arthritis and its impact on diagnostic estimates

    Article • BMC Musculoskeletal Disorders, June 2012, Springer Science + Business Media

    Dimitrios Ziogas

  33. FDG-PET for detecting local tumor recurrence of ablated liver metastases: a diagnostic meta-analysis

    Article • Biomarkers, June 2012, Informa Healthcare

    Dimitrios Ziogas

  34. Variants of the MTHFR gene and susceptibility to acute lymphoblastic leukemia in children: A synthesis of genetic association studies

    Article • Cancer Epidemiology, April 2012, Elsevier

    Dimitrios Ziogas, George Bakalos

  35. Evidence of Association BetweenMethylenetetrahydrofolate ReductaseGene and Susceptibility to Breast Cancer: A Candidate-Gene Association Study in a South-Eastern European Population

    Article • DNA and Cell Biology, February 2012, Mary Ann Liebert Inc

    Dimitrios Ziogas, George Bakalos

  36. Bone mineral density and genetic markers involved in three connected pathways (focal adhesion, actin cytoskeleton regulation and cell cycle): the CUMAGAS-BMD information system

    Article • Biomarkers, November 2011, Taylor & Francis

    Dimitrios Ziogas

  37. Oxidative stress and inflammatory markers in the exhaled breath condensate of children with OSA

    Article • Sleep And Breathing, August 2011, Springer Science + Business Media

    Dimitrios Ziogas

  38. A Network Meta-analysis of Randomized Controlled Trials of Induction Treatments in Acute Myeloid Leukemia in the Elderly

    Article • Clinical Therapeutics, March 2011, Elsevier

    Dimitrios Ziogas

  39. You deserve what you eat: lessons learned from the study of the melanin-concentrating hormone (MCH)-deficient mice

    Article • Gut, October 2010, BMJ

    Dimitrios Ziogas

  40. T1904 Predictors and Patterns of the Placebo Response in Gastro-Esophageal Reflux Disease: Meta-Analysis of Clinical Trials

    Article • Gastroenterology, May 2010, Elsevier

    Dimitrios Ziogas

  41. Meta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease

    Article • Alimentary Pharmacology & Therapeutics, March 2010, Wiley

    Dimitrios Ziogas

  42. Field Synopsis and Synthesis of Genetic Association Studies in Osteoarthritis: The CUMAGAS-OSTEO Information System

    Article • American Journal of Epidemiology, March 2010, Oxford University Press (OUP)

    Dimitrios Ziogas

  43. Serum correlates of the placebo effect in irritable bowel syndrome

    Article • Neurogastroenterology & Motility, March 2010, Wiley

    Dimitrios Ziogas

  44. MTHFRgene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis

    Article • Pharmacogenomics, August 2009, Future Medicine

    Dimitrios Ziogas

  45. Analysis of the Quality of Reporting of Randomized Controlled Trials in Acute and Chronic Myeloid Leukemia, and Myelodysplastic Syndromes as Governed by the CONSORT Statement

    Article • Annals of Epidemiology, July 2009, Elsevier

    Dimitrios Ziogas